Mesoblast Limited (MEOBF)
USD 1.37
(-52.76%)
USD 1.37
(-52.76%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -87.95 Million USD | -7.41% |
| 2023 | -81.88 Million USD | 10.35% |
| 2022 | -91.34 Million USD | 7.55% |
| 2021 | -98.81 Million USD | -26.78% |
| 2020 | -77.94 Million USD | 13.21% |
| 2019 | -89.79 Million USD | -154.46% |
| 2018 | -35.29 Million USD | 54.06% |
| 2017 | -76.81 Million USD | -1761.28% |
| 2016 | -4.12 Million USD | 96.54% |
| 2015 | -119.36 Million USD | -47.44% |
| 2014 | -80.95 Million USD | -31.29% |
| 2013 | -61.66 Million USD | 13.33% |
| 2012 | -71.14 Million USD | -178.52% |
| 2011 | 90.6 Million USD | 713.0% |
| 2010 | -14.78 Million USD | -20.31% |
| 2009 | -12.28 Million USD | -22.09% |
| 2008 | -10.06 Million USD | -15.29% |
| 2007 | -8.72 Million USD | -5.18% |
| 2006 | -8.29 Million USD | -464.39% |
| 2005 | -1.47 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -27.7 Million USD | -70.31% |
| 2024 Q4 | -27.7 Million USD | 0.0% |
| 2024 FY | -89.47 Million USD | -9.26% |
| 2024 Q1 | -16.26 Million USD | 25.56% |
| 2024 Q2 | -16.26 Million USD | 0.0% |
| 2023 Q3 | -18.6 Million USD | 24.04% |
| 2023 Q1 | -16.88 Million USD | 21.31% |
| 2023 Q4 | -21.85 Million USD | -17.51% |
| 2023 FY | -81.88 Million USD | 10.35% |
| 2023 Q2 | -24.48 Million USD | -45.02% |
| 2022 Q3 | -21.3 Million USD | 17.9% |
| 2022 Q4 | -21.45 Million USD | -0.72% |
| 2022 FY | -91.34 Million USD | 7.55% |
| 2022 Q1 | -22.64 Million USD | -2.65% |
| 2022 Q2 | -25.94 Million USD | -14.57% |
| 2021 Q2 | -25.69 Million USD | -4.68% |
| 2021 Q1 | -24.54 Million USD | 24.73% |
| 2021 Q4 | -22.06 Million USD | 16.8% |
| 2021 FY | -98.81 Million USD | -26.78% |
| 2021 Q3 | -26.51 Million USD | -3.2% |
| 2020 Q4 | -32.61 Million USD | -113.65% |
| 2020 FY | -77.94 Million USD | 13.21% |
| 2020 Q3 | -15.26 Million USD | 37.91% |
| 2020 Q2 | -24.58 Million USD | -348.29% |
| 2020 Q1 | -5.48 Million USD | 73.54% |
| 2019 Q3 | -24.97 Million USD | -1.49% |
| 2019 Q2 | -24.6 Million USD | -26.19% |
| 2019 Q1 | -19.49 Million USD | 6.41% |
| 2019 FY | -89.79 Million USD | -154.46% |
| 2019 Q4 | -20.72 Million USD | 17.0% |
| 2018 Q1 | -7.02 Million USD | 74.17% |
| 2018 FY | -35.29 Million USD | 54.06% |
| 2018 Q3 | -21.13 Million USD | -254.25% |
| 2018 Q2 | 13.7 Million USD | 295.14% |
| 2018 Q4 | -20.83 Million USD | 1.43% |
| 2017 Q3 | -9.78 Million USD | 51.2% |
| 2017 Q4 | -27.18 Million USD | -177.82% |
| 2017 FY | -76.81 Million USD | -1761.28% |
| 2017 Q2 | -20.05 Million USD | -1.28% |
| 2017 Q1 | -19.79 Million USD | -141.0% |
| 2016 Q2 | -22.32 Million USD | -69.64% |
| 2016 Q3 | -16.93 Million USD | 24.15% |
| 2016 FY | -4.12 Million USD | 96.54% |
| 2016 Q1 | -13.16 Million USD | 75.49% |
| 2016 Q4 | 48.29 Million USD | 385.19% |
| 2015 Q3 | -22.24 Million USD | 20.23% |
| 2015 Q4 | -53.7 Million USD | -141.44% |
| 2015 Q2 | -27.88 Million USD | -79.36% |
| 2015 Q1 | -15.54 Million USD | 33.04% |
| 2015 FY | -119.36 Million USD | -47.44% |
| 2014 Q2 | -16.35 Million USD | -39.27% |
| 2014 Q4 | -23.21 Million USD | 1.05% |
| 2014 FY | -80.95 Million USD | -31.29% |
| 2014 Q1 | -11.74 Million USD | 24.25% |
| 2014 Q3 | -23.46 Million USD | -43.41% |
| 2013 Q4 | -15.5 Million USD | 12.05% |
| 2013 FY | -61.66 Million USD | 13.33% |
| 2013 Q3 | -17.63 Million USD | 0.0% |
| 2012 FY | -71.14 Million USD | -178.52% |
| 2011 FY | 90.6 Million USD | 713.0% |
| 2010 FY | -14.78 Million USD | -20.31% |
| 2009 FY | -12.28 Million USD | -22.09% |
| 2008 FY | -10.06 Million USD | -15.29% |
| 2007 FY | -8.72 Million USD | -5.18% |
| 2006 FY | -8.29 Million USD | -464.39% |
| 2005 FY | -1.47 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -6486.338% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -1159.603% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 266.02% |
| Nascent Biotech, Inc. | -2.08 Million USD | -4113.094% |
| Rebus Holdings, Inc. | -1.02 Million USD | -8523.137% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 235.041% |
| Qrons Inc. | -789.34 Thousand USD | -11042.881% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -13808.132% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | -40.507% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -21069.782% |
| Skye Bioscience, Inc. | -37.64 Million USD | -133.647% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | -17.333% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -1237.508% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -32070.942% |
| SQZ Biotechnologies Company | -79.46 Million USD | -10.687% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -2940.941% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -4731.346% |
| Marizyme, Inc. | -65.34 Million USD | -34.599% |
| Genus plc | 7.9 Million USD | 1213.367% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -707.548% |
| Pharming Group N.V. | -10.54 Million USD | -733.864% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -3953.619% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -2270.632% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -894.527% |
| ContraFect Corporation | -65.15 Million USD | -34.999% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -1700.141% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -4991.652% |
| IMV Inc. | -36.48 Million USD | -141.07% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -991.309% |
| MultiCell Technologies, Inc. | -380.07 USD | -23141952.78% |
| ONE Bio Corp. | 8.67 Million USD | 1113.714% |
| Accustem Sciences Inc. | -3.74 Million USD | -2247.735% |
| RVL Pharmaceuticals plc | -51.69 Million USD | -70.154% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -6841.334% |
| Q BioMed Inc. | -2.05 Million USD | -4186.161% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -2256.175% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -3594.28% |
| Biomind Labs Inc. | -1.21 Million USD | -7143.237% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | -47.267% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -2735.673% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -1012.931% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -4412.302% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -587213.034% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -454.178% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -1411.985% |
| GB Sciences, Inc. | -1.36 Million USD | -6359.388% |
| Alpha Cognition Inc. | -13.77 Million USD | -538.632% |
| HST Global, Inc. | -146.21 Thousand USD | -60057.308% |
| CSL Limited | 2.64 Billion USD | 103.329% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -4912.392% |
| Halberd Corporation | -79.67 Thousand USD | -110292.088% |
| Enzolytics Inc. | -2.17 Million USD | -3940.551% |
| Agentix Corp. | -1.37 Million USD | -6300.473% |
| Resverlogix Corp. | -3.61 Million USD | -2336.454% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -2673.381% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 70.19% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 89851.02% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 1370.197% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -2113.847% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -2806.546% |
| AVAX Technologies, Inc. | -6.41 Million USD | -1271.388% |
| Zenith Capital Corp. | -10.59 Million USD | -730.087% |
| Genscript Biotech Corporation | -95.47 Million USD | 7.877% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -378335.591% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -2021.499% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -145424.673% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -4286.581% |
| Kadimastem Ltd | -3.3 Million USD | -2559.372% |
| Helix BioMedix, Inc. | -1.05 Million USD | -8228.717% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -2203.116% |
| BioStem Technologies, Inc. | -8.48 Million USD | -936.852% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -19827.997% |
| LadRx Corporation | 400.44 Thousand USD | 22064.674% |
| Cell Source, Inc. | -5.32 Million USD | -1552.932% |
| Regen BioPharma, Inc. | 1.02 Million USD | 8693.582% |
| Regen BioPharma, Inc. | 1.02 Million USD | 8693.582% |
| NovAccess Global Inc. | -4.76 Million USD | -1744.256% |
| Affymax, Inc. | -14.42 Million USD | -509.789% |
| Itoco Inc. | -1.86 Million USD | -4606.059% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1879.861% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -5169.982% |
| Mobile Lads Corp. | -2.26 Million USD | -3786.198% |
| CytoDyn Inc. | -49.84 Million USD | -76.473% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -111190.221% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -38455.717% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -9241.826% |
| SYBLEU INC | -180.3 Thousand USD | -48682.057% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -5353.834% |
| International Stem Cell Corporation | -131 Thousand USD | -67041.985% |
| Bioxytran, Inc. | -4.28 Million USD | -1955.046% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -161965.153% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -3376.182% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -82.967% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -4060.643% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -11163.602% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -2676.389% |
| Neutra Corp. | -233.46 Thousand USD | -37574.17% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -333.473% |
| PureTech Health plc | -65.69 Million USD | -33.881% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -313.589% |
| IXICO plc | -1.17 Million USD | -7366.553% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -786.028% |
| Gelesis Holdings, Inc. | -57.12 Million USD | -53.963% |
| CSL Limited | 2.64 Billion USD | 103.329% |
| Cellectis S.A. | -103.17 Million USD | 14.75% |